Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antileukemic agents.

Elpis Mantadakis1, Maria Kalmanti

  • 1Pediatric Hematology/Oncology Clinic, University Hospital of Heraklion, Heraklion, Crete, Greece.

Pediatric Hematology and Oncology
|March 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric Oral Iron Therapy: Choosing the Right Product for Your Patient.

Hematology reports·2026
Same author

Invasive Meningococcal Disease in Children: Outcomes and Risk Factors for Sequelae and Fatal Cases in Greece.

Microorganisms·2025
Same author

Emergency Identification of Endotracheal Tube Tip via Ultrasonography Used by Trained Nurse in the Neonatal Intensive Care Unit (NICU).

Diagnostics (Basel, Switzerland)·2025
Same author

Oral Iron-Hydroxide Polymaltose Complex Versus Sucrosomial Iron for Children with Iron Deficiency with or without Anemia: A Clinical Trial with Emphasis on Intestinal Inflammation.

Mediterranean journal of hematology and infectious diseases·2024
Same author

Transfusion-related acute lung injury/transfusion-associated circulatory overload in a child with non-transfusion dependent thalassemia and aplastic crisis due to acute parvovirus B19 infection.

BMJ case reports·2024
Same author

The evolving genetic landscape of telomere biology disorder dyskeratosis congenita.

EMBO molecular medicine·2024

New antileukemic agents are needed for childhood leukemia subgroups with poor prognosis. This review covers novel compounds and their clinical development concepts, crucial for pediatric hematologists/oncologists.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Pharmacology

Background:

  • Childhood leukemias have seen treatment advances, but some patient groups still face poor outcomes.
  • There is a critical need for novel therapeutic strategies and antileukemic agents in pediatric oncology.

Purpose of the Study:

  • To review the clinical trial results of emerging antileukemic compounds.
  • To discuss the clinical development concepts of new agents for pediatric hematologists/oncologists.

Main Methods:

  • Literature review of clinical trials involving new antileukemic compounds.
  • Analysis of compounds with diverse mechanisms of action, including signal transduction inhibitors, nucleoside analogs, DNA hypomethylators, angiogenesis inhibitors, and monoclonal antibodies.

Related Experiment Videos

Main Results:

  • Several new antileukemic compounds targeting different pathways have shown promise in clinical trials.
  • While not all compounds are currently used in pediatric leukemias, their development principles are relevant.

Conclusions:

  • The development of novel antileukemic agents is essential for improving outcomes in pediatric leukemia subgroups with poor prognosis.
  • Understanding the clinical development of these new agents is vital for advancing pediatric hematology/oncology practice.